News | March 31, 2026
Granules Life Sciences receives VAI Classification for Shamirpet facility
The inspection is now closed, and no regulatory action has been recommended
The inspection is now closed, and no regulatory action has been recommended
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
The initial consideration for the transaction is US$ 12 million
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Subscribe To Our Newsletter & Stay Updated
